<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0509234131
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1986
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TRIMOL SUSP.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SULFAMETHOXAZOLE,TRIMETHOPRIM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40,8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Syrup
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        17.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01EE01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trimol Suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5mL of the suspension contains: 
Item No.	Material Name	Scale (mg/5mL)
		
	Active Ingredients:	
1.		Trimethoprim (micronized)	40.00
2.		Sulphamethoxazole (Micronized)	200.00
		
	Inactive Ingredients:	
1.		Glycerol 	350.00
2.		Saccharin sodium	5.00
3.		Citric acid monohydrate	3.00
4.		Sucrose	2200.00
5.		Tween 80	20.00
6.		Apricot flavour	5.00
7.		Banana flavour	5.00
8.		Raspberry red colour	0.035
9.		FD&C red 40	0.025
10.		CMC sodium	22.50
11.		Aluminium magnesium silicate (veegum HV)	20.00
12.		Methyl paraben	5.00
13.		Propyl paraben	1.50
14.		Propylene glycol	400.00
15.		Sorbitol 70%	375.00
16.		Polyvinyl pyrrolidone (PVP-K-30)	5.00
17.		Colloidal silicon dioxide (Aerosil 200)	12.50
18.		Purified water.	q.s. to 5mL

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral Suspension
Description: Light pink suspension, fruity odour with palatable taste.   

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Trimol</strong> Paediatric Suspension is indicated in children aged 12 years and under (infants (&gt;6 weeks to &lt;2 years old) and children (&gt;2 to &lt;12 years old) for the treatment of the following infections when owing to sensitive organisms (see section 5.1) :</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]--><em>Urinary tract infections: </em>For simple urinary tract infections, trimethoprim alone or another single antimicrobial agent is the preferred treatment. Since trimethoprim is also as efficacious as co-Trimoxazole for the prophylaxis of recurrent urinary tract infections, co-Trimoxazole is not indicated for prophylactic use.&nbsp;&nbsp;</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]--><em>Respiratory tract infections: </em>Co-Trimoxazole may be used as second line therapy in chronic obstructive airways disease or other respiratory tract infections, including acute otitis media where sensitivity has been demonstrated or is highly probable.</p><p style="margin-left:18.0pt; text-align:justify">(Co-Trimoxazole is not indicated for prophylactic or prolonged administration in otitis media).</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Treatment and prevention of <em>Pneumocystis jirovecii pneumonitis (PJP)</em>.</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Co-Trimoxazole may be used in the management of other serious conditions such as nocardiasis, toxoplasmosis and brucellosis.</p><p style="text-align:justify">Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong><u>Posology:</u></strong></p><p style="text-align:justify"><strong><u>Standard dosage recommendations for acute infections</u></strong></p><p style="text-align:justify"><em>Children aged 12 years and under (infants (&gt;6 weeks to &lt;2 years old) and children (&gt;2 to &lt;12 years old)</em></p><p style="text-align:justify">The standard dosage for children is equivalent to approximately 6 mg trimethoprim and 30 mg sulphamethoxazole per kg body weight per day, given in two equally divided doses. The schedules for children are according to the child&#39;s age and provided in the table below:</p><table cellspacing="0" cellpadding="0" border="1" style="width:396.0pt"><tbody><tr><td colspan="2" style="vertical-align:top; width:100.0%"><p style="text-align:justify"><strong>STANDARD DOSAGE</strong></p></td></tr><tr><td style="vertical-align:top; width:43.18%"><p style="text-align:justify"><strong>Age</strong></p></td><td style="vertical-align:top; width:56.82%"><p style="text-align:justify"><strong>Paediatric Suspension</strong></p></td></tr><tr><td style="vertical-align:top; width:43.18%"><p style="text-align:justify">6 to 12 years</p></td><td style="vertical-align:top; width:56.82%"><p style="text-align:justify">10 ml every 12 hours</p></td></tr><tr><td style="vertical-align:top; width:43.18%"><p style="text-align:justify">6 months to 5 years</p></td><td style="vertical-align:top; width:56.82%"><p style="text-align:justify">5 ml every 12 hours</p></td></tr><tr><td style="vertical-align:top; width:43.18%"><p style="text-align:justify">6 weeks to 5 months</p></td><td style="vertical-align:top; width:56.82%"><p style="text-align:justify">2.5 ml every 12 hours</p></td></tr></tbody></table><p style="text-align:justify">Treatment should be continued until the patient has been symptom free for two days; the majority will require treatment for at least 5 days. If clinical improvement is not evident after 7 days therapy, the patient should be reassessed.</p><p style="text-align:justify">As an alternative to Standard Dosage for acute uncomplicated lower urinary tract infections, short-term therapy of 1 to 3 days duration has been shown to be effective.</p><p style="text-align:justify"><strong>Impaired hepatic function:</strong></p><p style="text-align:justify">No data are available relating to dosage in patients with impaired hepatic function.</p><p style="text-align:justify"><strong>Impaired renal function:</strong></p><p style="text-align:justify"><strong><u>Dosage recommendation</u></strong><strong>:</strong></p><p style="text-align:justify"><em>Adults (&gt;18 years old) and children over 12 years old (&gt;12 to &lt;18 years old):</em></p><table cellspacing="0" cellpadding="0" border="1" style="width:396.0pt"><tbody><tr><td style="vertical-align:top; width:43.18%"><p style="text-align:justify"><strong>Creatinine Clearance (ml/min)</strong></p></td><td style="vertical-align:top; width:56.82%"><p style="text-align:justify"><strong>Recommended Dosage</strong></p></td></tr><tr><td style="vertical-align:top; width:43.18%"><p style="text-align:justify">&gt;30</p></td><td style="vertical-align:top; width:56.82%"><p style="text-align:justify">10 ml every 12 hours</p></td></tr><tr><td style="vertical-align:top; width:43.18%"><p style="text-align:justify">15 to 30</p></td><td style="vertical-align:top; width:56.82%"><p style="text-align:justify">5 ml every 12 hours</p></td></tr><tr><td style="vertical-align:top; width:43.18%"><p style="text-align:justify">&lt;15</p></td><td style="vertical-align:top; width:56.82%"><p style="text-align:justify">Not recommended</p></td></tr></tbody></table><p style="text-align:justify">No information available for children aged 12 years and under with renal failure. See section 5.2 for the pharmacokinetics in the paediatric population with normal renal function of both components of Co-Trimoxazole .</p><p style="text-align:justify">Measurements of plasma concentration of sulphamethoxazole at intervals of 2 to 3 days are recommended in samples obtained 12 hours after administration of Co-Trimoxazole. If the concentration of total sulphamethoxazole exceeds 150 microgram/ml then treatment should be interrupted until the value falls below 120 microgram/ml.</p><p style="text-align:justify"><strong><u>Pneumocystis jirovecii pneumonitis:</u></strong></p><p style="text-align:justify"><em>Treatment -&nbsp;Children aged 12 years and under (infants (&gt;6 weeks to &lt;2 years old) and children (&gt;2 to &lt;12 years old):</em></p><p style="text-align:justify">A higher dosage is recommended, using 20 mg trimethoprim and 100 mg sulphamethoxazole per kg of body weight per day (see table below) in two or more divided doses for two weeks. The aim is to obtain peak plasma or serum levels of trimethoprim of&nbsp;<u>greater than or equal to</u>&nbsp;5 microgram/ml (verified in patients receiving 1-hour infusions of intravenous Co-Trimoxazole) (see section 4.8).</p><p style="text-align:justify"><em>Prevention -&nbsp;Children aged 12 years and under (infants (&gt;6 weeks to &lt;2 years old) and children (&gt;2 to &lt;12 years old):</em></p><p style="text-align:justify">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1" style="width:400.5pt"><tbody><tr><td style="vertical-align:top; width:33.64%"><p style="text-align:justify"><strong>Age</strong></p></td><td style="vertical-align:top; width:66.36%"><p style="text-align:justify"><strong>Paediatric Suspension</strong></p></td></tr><tr><td style="vertical-align:top; width:33.64%"><p style="text-align:justify">6 to 12 years</p></td><td style="vertical-align:top; width:66.36%"><p style="text-align:justify">10 ml every 12 hours, seven days per week</p></td></tr><tr><td style="vertical-align:top; width:33.64%"><p style="text-align:justify">6 to 12 years</p></td><td style="vertical-align:top; width:66.36%"><p style="text-align:justify">10 ml every 12 hours, three times per week on alternative days</p></td></tr><tr><td style="vertical-align:top; width:33.64%"><p style="text-align:justify">6 to 12 years</p></td><td style="vertical-align:top; width:66.36%"><p style="text-align:justify">10 ml every 12 hours, three times per week on consecutive days</p></td></tr><tr><td style="vertical-align:top; width:33.64%"><p style="text-align:justify">6 to 12 years</p></td><td style="vertical-align:top; width:66.36%"><p style="text-align:justify">20 ml once a day, three times per week on consecutive days</p></td></tr><tr><td style="vertical-align:top; width:33.64%"><p style="text-align:justify">6 months to 5 years</p></td><td style="vertical-align:top; width:66.36%"><p style="text-align:justify">5 ml every 12 hours, seven days per week</p></td></tr><tr><td style="vertical-align:top; width:33.64%"><p style="text-align:justify">6 months to 5 years</p></td><td style="vertical-align:top; width:66.36%"><p style="text-align:justify">5 ml every 12 hours, three times per week on alternative days</p></td></tr><tr><td style="vertical-align:top; width:33.64%"><p style="text-align:justify">6 months to 5 years</p></td><td style="vertical-align:top; width:66.36%"><p style="text-align:justify">5 ml every 12 hours, three times per week on consecutive days</p></td></tr><tr><td style="vertical-align:top; width:33.64%"><p style="text-align:justify">6 months to 5 years</p></td><td style="vertical-align:top; width:66.36%"><p style="text-align:justify">10 ml once a day, three times per week on consecutive days</p></td></tr><tr><td style="vertical-align:top; width:33.64%"><p style="text-align:justify">6 weeks to 5 months</p></td><td style="vertical-align:top; width:66.36%"><p style="text-align:justify">2.5 ml every 12 hours, seven days per week</p></td></tr><tr><td style="vertical-align:top; width:33.64%"><p style="text-align:justify">6 weeks to 5 months</p></td><td style="vertical-align:top; width:66.36%"><p style="text-align:justify">2.5 ml every 12 hours, three times per week on alternative days</p></td></tr><tr><td style="vertical-align:top; width:33.64%"><p style="text-align:justify">6 weeks to 5 months</p></td><td style="vertical-align:top; width:66.36%"><p style="text-align:justify">2.5 ml every 12 hours, three times per week on consecutive days</p></td></tr><tr><td style="vertical-align:top; width:33.64%"><p style="text-align:justify">6 weeks to 5 months</p></td><td style="vertical-align:top; width:66.36%"><p style="text-align:justify">5 ml once a day, three times per week on consecutive days</p></td></tr></tbody></table><p style="text-align:justify">The daily dose given on a treatment day approximates to 150 mg trimethoprim/m<sup>2</sup>/day and 750 mg sulphamethoxazole/m<sup>2</sup>/day. The total daily dose should not exceed 320 mg trimethoprim and 1600 mg sulphamethoxazole.</p><p style="text-align:justify"><strong>Nocardiosis </strong></p><p style="text-align:justify">There is no consensus on the most appropriate dosage. Adult doses of 480 mg trimethoprim/2400 mg sulphamethoxazole to 640 mg trimethoprim/3200 mg sulphamethoxazole daily for up to three months have been used.</p><p style="text-align:justify"><strong>Brucellosis </strong></p><p style="text-align:justify">It may be advisable to use a higher than standard dosage initially. Treatment should continue for a period of at least four weeks and repeated courses may be beneficial. Co-trimoxazole should be given in combination with other agents in line with national treatment guidelines.</p><p style="text-align:justify"><strong>Toxoplasmosis </strong></p><p style="text-align:justify">There is no consensus on the most appropriate dosage for the treatment or prophylaxis of this condition. The decision should be based on clinical experience. Doses of 480 mg or 960 mg of trimethoprim - sulphamethoxazole twice daily for three months have been used for prophylaxis and 40 mg/kg/day or 120 mg/kg/day for a mean of 25 days for the treatment of toxoplasmosis in patients with HIV.</p><p style="text-align:justify"><strong><u>Method of administration </u></strong></p><p style="text-align:justify">Oral</p><p style="text-align:justify">It may be preferable to take co-trimoxazole with some food or drink to minimise the possibility of gastrointestinal disturbances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Co-trimoxazole Paediatric suspension is contraindicated in patients with:
	Hypersensitivity to the active substance(s) sulphonamides, trimethoprim or to any of the excipients listed in section 6.1.
	Severe renal insufficiency where repeated measurements of the plasma drug concentration cannot be performed.
	Severe impairment of liver function.
	A history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulphonamides.
	Acute porphyria.
	Co-trimoxazole should not be given to infants during the first 6 weeks of life.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Fatalities, although very rare, have occurred due to severe reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, other blood dyscrasias and hypersensitivity of the respiratory tract.</p><p style="text-align:justify"><strong><u>Life threatening adverse reaction</u></strong></p><p style="margin-left:9.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Life-threatening cutaneous reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with the use of co-trimoxazole.</p><p style="margin-left:9.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS or TEN is within the first weeks of treatment.</p><p style="margin-left:9.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) are present, co-trimoxazole treatment should be discontinued (see section 4.8).</p><p style="margin-left:9.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->The best results in managing SJS and TEN come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis.</p><p style="margin-left:9.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->If the patient has developed SJS or TEN with the use of co-trimoxazole, co-trimoxazole must not be re-started in this patient at any time.</p><p style="text-align:justify"><strong><u>Elderly patients</u></strong></p><p style="text-align:justify">Particular care is always advisable when treating elderly patients because, as a group, they are more susceptible to adverse reactions and more likely to suffer serious effects as a result particularly when complicating conditions exist, e.g. impaired kidney and/or liver function and/or concomitant use of other drugs.</p><p style="text-align:justify"><strong><u>Patients with renal impairment</u></strong></p><p style="text-align:justify">For patients with known renal impairment special measures should be adopted (see section 4.2).</p><p style="text-align:justify"><strong><u>Urinary output</u></strong></p><p style="text-align:justify">An adequate urinary output should be maintained at all times. Evidence of crystalluria in vivo is rare, although sulphonamide crystals have been noted in cooled urine from treated patients. In patients suffering from hypoalbuminaemia the risk may be increased.</p><p style="text-align:justify"><strong><u>Folate </u></strong></p><p style="text-align:justify">Regular monthly blood counts are advisable when co-trimoxazole is given for long periods, or to folate deficient patients or to the elderly; since there exists a possibility of asymptomatic changes in haematological laboratory indices due to lack of available folate. Supplementation with folinic acid may be considered during treatment but this should be initiated with caution due to possible interference with antimicrobial efficacy (see section 4.5).</p><p style="text-align:justify"><strong><u>Patients with glucose-6-phosphate dehydrogenase deficiency</u></strong></p><p style="text-align:justify">In glucose-6-phosphate dehydrogenase (G-6-PD) deficient patients, haemolysis may occur.</p><p style="text-align:justify"><strong><u>Patients with severe atopy or bronchial asthma</u></strong></p><p style="text-align:justify">Co-trimoxazole should be given with caution to patients with severe atopy or bronchial asthma.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong><u>Treatment of streptococcal pharyngitis due to Group A beta-haemolytic streptococci</u></strong></p><p style="text-align:justify">Co-trimoxazole should not be used in the treatment of streptococcal pharyngitis due to Group A &beta;-haemolytic streptococci; eradication of these organisms from the oropharynx is less effective than with penicillin.</p><p style="text-align:justify"><strong><u>Phenylalanine metabolism</u></strong></p><p style="text-align:justify">Trimethoprim has been noted to impair phenylalanine metabolism but this is of no significance in phenylketonuric patients on appropriate dietary restriction.</p><p style="text-align:justify"><strong><u>Patients with or at risk of porphyria</u></strong></p><p style="text-align:justify">The administration of co-trimoxazole to patients known or suspected to be at risk of porphyria should be avoided. Both trimethoprim and sulphonamides (although not specifically sulphamethoxazole) have been associated with clinical exacerbation of porphyria.</p><p style="text-align:justify"><strong><u>Patients with hyperkalaemia and hyponatraemia</u></strong></p><p style="text-align:justify">Close monitoring of serum potassium is warranted in patients at risk of hyperkalaemia and hyponatraemia.</p><p style="text-align:justify"><strong><u>Metabolic acidosis&nbsp; </u></strong></p><p style="text-align:justify">Co-trimoxazole has been associated with metabolic acidosis when other possible underlying causes have been excluded. Close monitoring is always advisable when metabolic acidosis is suspected.</p><p style="text-align:justify"><strong><u>Patients with serious haematological disorders</u></strong></p><p style="text-align:justify">Except under careful supervision co-trimoxazole should not be given to patients with serious haematological disorders (see section 4.8). Co-trimoxazole has been given to patients receiving cytotoxic therapy with little or no additional effect on the bone marrow or peripheral blood.</p><p style="text-align:justify">Patients with rare hereditary problems of fructose intolerance should not take this medicine (see section 2).</p><p style="text-align:justify"><strong>Trimol</strong> Suspension contains:</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Methyl paraben and propyl paraben, which may cause allergic reactions (possibly delayed).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Diuretics (thiazides)</u>: in elderly patients concurrently receiving diuretics, mainly thiazides, there appears to be an increased risk of thrombocytopenia with or without purpura.</p><p style="text-align:justify"><u>Pyrimethamine:&nbsp;</u>occasional reports suggest that patients receiving pyrimethamine at doses in excess of 25 mg weekly may develop megaloblastic anaemia should co-trimoxazole be prescribed concurrently.</p><p style="text-align:justify"><u>Zidovudine</u>: in some situations, concomitant treatment with zidovudine may increase the risk of haematological adverse reactions to co-trimoxazole. If concomitant treatment is necessary, consideration should be given to monitoring of haematological parameters.</p><p style="text-align:justify"><u>Lamivudine:</u>&nbsp;administration of trimethoprim/sulphamethoxazole 160 mg/800 mg (co-trimoxazole) causes a 40% increase in lamivudine exposure because of the trimethoprim component. Lamivudine has no effect on the pharmacokinetics of trimethoprim or sulphamethoxazole.</p><p style="text-align:justify"><u>Warfarin</u>: co-trimoxazole has been shown to potentiate the anticoagulant activity of warfarin via stereo-selective inhibition of its metabolism. Sulphamethoxazole may displace warfarin from plasma-albumin protein-binding sites&nbsp;<em>in vitro</em>. Careful control of the anticoagulant therapy during treatment with Co-trimoxazole is advisable.</p><p style="text-align:justify"><u>Phenytoin</u>: co-trimoxazole prolongs the half-life of phenytoin and if co-administered excessive phenytoin effect. Close monitoring of the patient&#39;s condition and serum phenytoin levels are advisable.</p><p style="text-align:justify">Interaction with&nbsp;<u>sulphonylurea hypoglycaemic agents&nbsp;</u>is uncommon but potentiation has been reported.</p><p style="text-align:justify"><u>Rifampicin:</u>&nbsp;concurrent use of rifampicin and Co-trimoxazole results in a shortening of the plasma half-life of trimethoprim after a period of about one week. This is not thought to be of clinical significance.</p><p style="text-align:justify"><u>Cyclosporin</u>: reversible deterioration in renal function has been observed in patients treated with co-trimoxazole and cyclosporin following renal transplantation.</p><p style="text-align:justify">When trimethoprim is administered simultaneously with drugs that form cations at physiological pH, and are also partly excreted by active renal secretion (e.g.&nbsp;<u>procainamide, amantadine</u>), there is the possibility of competitive inhibition of this process which may lead to an increase in plasma concentration of one or both of the drugs.</p><p style="text-align:justify"><u>Digoxin</u>: concomitant use of trimethoprim with digoxin has been shown to increase plasma digoxin levels in a proportion of elderly patients.</p><p style="text-align:justify"><u>Hyperkalaemia:&nbsp;</u>caution should be exercised in patients taking any other drugs that can cause hyperkalaemia, for example ACE inhibitors, angiotensin receptor blockers and potassium-sparing diuretics such as spironolactone. Concomitant use of trimethoprim-sulphamethoxazole (co-trimoxazole) may result in clinically relevant hyperkalaemia. <u>Azathioprine:</u>&nbsp;There are conflicting clinical reports of interactions, resulting in serious haematological abnormalities, between azathioprine and co-trimoxazole.</p><p style="text-align:justify"><u>Methotrexate:&nbsp;</u>co-trimoxazole may increase the free plasma levels of methotrexate. If Co-trimoxazole is considered appropriate therapy in patients receiving other anti-folate drugs such as methotrexate, a folate supplement should be considered. (see section 4.4)</p><p style="text-align:justify"><u>Repaglinide</u>: trimethoprim may increase the exposure of repaglinide which may result in hypoglycaemia.</p><p style="text-align:justify"><u>Folinic acid</u>: folinic acid supplementation has been shown to interfere with the antimicrobial efficacy of trimethoprim-sulphamethoxazole. This has been observed in&nbsp;<em>Pneumocystis jiroveci pneumonia</em>&nbsp;prophylaxis and treatment.</p><p style="text-align:justify"><u>Contraceptives</u>: oral contraceptive failures have been reported with antibiotics. The mechanism of this effect has not been elucidated. Women on treatment with antibiotics should temporarily use a barrier method in addition to the oral contraceptive, or choose another method of contraception<u>.</u></p><p style="text-align:justify"><strong><u>Interaction with laboratory tests</u></strong><strong>:</strong></p><p style="text-align:justify">Trimethoprim interferes with assays for serum methotrexate when dihydrofolate reductase from&nbsp;<em>Lactobacillus</em>&nbsp;<em>casei&nbsp;</em>is used in the assay. No interference occurs if methotrexate is measured by radio-immune assay.</p><p style="text-align:justify">Trimethoprim may interfere with the estimation of serum/plasma creatinine when the alkaline picrate reaction is used. This may result in overestimation of serum/plasma creatinine of the order of 10%.</p><p style="margin-left:0cm; margin-right:0cm; text-align:justify">Functional inhibitation of the renal tubular secretion of creatinine may produce a spurious fall in the estimated rate of creatinine clearance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong><u>Pregnancy </u></strong></p><p style="text-align:justify">Trimethoprim and sulphamethoxazole cross the placenta and their safety in human pregnancy has not been established. Trimethoprim is a folate antagonist and, in animal studies, both agents have been shown to cause foetal abnormalities (see section 5.3). Case-control studies have shown that there may be an association between exposure to folate antagonists and birth defects in humans. Therefore Co-trimoxazole should be avoided in pregnancy, particularly in the first trimester, unless the potential benefit to the mother outweighs the potential risk to the foetus; folate supplementation should be considered if Co-trimoxazole is used in pregnancy</p><p style="text-align:justify">Sulphamethoxazole competes with bilirubin for binding to plasma albumin. As significant maternally derived drug levels persist for several days in the newborn, there may be a risk of precipitating or exacerbating neonatal hyperbilirubinaemia, with an associated theoretical risk of kernicterus, when Co-trimoxazole is administered to the mother near the time of delivery. This theoretical risk is particularly relevant in infants at increased risk of hyperbilirubinaemia, such as those who are preterm and those with glucose-6- phosphate dehydrogenase deficiency.</p><p style="text-align:justify"><strong><u>Breast Feeding </u></strong></p><p>Trimethoprim and sulphamethoxazole are excreted in breast milk. Administration of Co-trimoxazole should be avoided in late pregnancy and in lactating mothers where the mother or infant has, or is at particular risk of developing, hyperbilirubinaemia. Additionally, administration of Co-trimoxazole should be avoided in infants younger than eight weeks in view of the predisposition of young infants to hyperbilirubinaemia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Effects on the ability to drive and operate machinery in patients taking this medicine have not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">As co-trimoxazole contains trimethoprim and a sulphonamide the type and frequency of adverse reactions associated with such compounds are expected to be consistent with extensive historical experience.</p><p style="text-align:justify">Data from large published clinical trials were used to determine the frequency of very common to rare adverse events. Very rare adverse events were primarily determined from post-marketing experience data and therefore refer to reporting rate rather than a &quot;true&quot; frequency. In addition, adverse events may vary in their incidence depending on the indication.</p><p style="text-align:justify">The following convention has been used for the classification of adverse events in terms of frequency:</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Very common &ge;1/10,</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Common &ge;1/100 and &lt;1/10,</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Uncommon &ge;1/1000 and &lt;1/100,</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-9.0pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Rare &ge;1/10,000 and &lt;1/1000,</p><p style="margin-left:18.7pt; margin-right:0cm; text-align:justify; text-indent:-9.35pt"><!--[if !supportLists]-->&sect; <!--[endif]-->Very rare &lt;1/10,000.</p><table cellspacing="0" cellpadding="0" border="1" style="width:400.5pt"><tbody><tr><td style="vertical-align:top; width:30.34%"><p style="text-align:justify"><strong>System Organ Class</strong></p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify"><strong>Frequency</strong></p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify"><strong>Side effects</strong></p></td></tr><tr><td style="height:23.0pt; vertical-align:top; width:30.34%"><p style="text-align:justify">Infections and infestations</p></td><td style="height:23.0pt; vertical-align:top; width:19.1%"><p style="text-align:justify">Common</p></td><td style="height:23.0pt; vertical-align:top; width:50.56%"><p style="text-align:justify">Overgrowth fungal.</p></td></tr><tr><td style="vertical-align:top; width:30.34%"><p style="text-align:justify">Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Leukopenia, neutropenia, thrombocytopenia, agranulocytosis, anaemia megaloblastic, aplastic anaemia, haemolytic anaemia, methaemoglobinaemia, eosinophilia, purpura, haemolysis in certain susceptible G-6-PD deficient patients.</p></td></tr><tr><td style="vertical-align:top; width:30.34%"><p style="text-align:justify">Immune system disorders</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Serum sickness, anaphylactic reaction, allergic myocarditis, hypersensitivity vasculitis resembling Henoch-Schoenlein purpura, periarteritis nodosa, systemic lupus erythematosus.</p><p style="text-align:justify">Severe hypersensitivity reactions associated with PJP* including rash, pyrexia, neutropenia, thrombocytopenia, hepatic enzyme increased, hyperkalaemia, hyponatraemia, rhabdomyolysis</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:30.34%"><p style="text-align:justify">Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very common</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Hyperkalaemia.</p></td></tr><tr><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Hypoglycaemia, hyponatraemia, decreased appetite, metabolic acidosis</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:30.34%"><p style="text-align:justify">Psychiatric disorders</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Depression, hallucination.</p></td></tr><tr><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Not known</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Psychotic disorder</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:30.34%"><p style="text-align:justify">Nervous system disorders</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Common</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Headache.</p></td></tr><tr><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Meningitis aseptic *, seizure, neuropathy peripheral, ataxia, dizziness.</p></td></tr><tr><td style="vertical-align:top; width:30.34%"><p style="text-align:justify">Ear and labrynth disroders</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Vertigo, tinnitus</p></td></tr><tr><td style="vertical-align:top; width:30.34%"><p style="text-align:justify">Eye disorders</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Uveitis.</p></td></tr><tr><td style="vertical-align:top; width:30.34%"><p style="text-align:justify">Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Cough*, dyspnoea *, lung infiltration*.</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:30.34%"><p style="text-align:justify">Gastrointestinal disorders</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Common</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Nausea, diarrhoea.</p></td></tr><tr><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Uncommon</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Vomiting.</p></td></tr><tr><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Glossitis, stomatitis, pseudomembranous, colitis, pancreatitis.</p></td></tr><tr><td style="vertical-align:top; width:30.34%"><p style="text-align:justify">Hepatobiliary disorders</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Jaundice cholestatic *, hepatic necrosis*</p><p style="text-align:justify">Transaminases increased, blood bilirubin increased.</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:30.34%"><p style="text-align:justify">Skin and subcutaneous tissue disorders*</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Common</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Rash.</p></td></tr><tr><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Photosensitivity reaction, angioedema, dermatitis exfoliative, fixed drug eruption, erythema multiforme, Stevens-Johnson syndrome (SJS)*, toxic epidermal necrolysis (TEN)*.</p></td></tr><tr><td style="vertical-align:top; width:30.34%"><p style="text-align:justify">Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Arthralgia, myalgia.</p></td></tr><tr><td style="vertical-align:top; width:30.34%"><p style="text-align:justify">Renal and urinary disorders</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Renal impairment (sometimes reported as renal failure), tubulointerstitial nephritis.</p></td></tr><tr><td style="vertical-align:top; width:30.34%"><p style="text-align:justify">General disorders and administration site conditions</p></td><td style="vertical-align:top; width:19.1%"><p style="text-align:justify">Very rare</p></td><td style="vertical-align:top; width:50.56%"><p style="text-align:justify">Pyrexia.</p></td></tr></tbody></table><p style="text-align:justify">* see description of selected adverse reactions</p><p style="text-align:justify"><strong><u>Description of selected adverse reactions </u></strong></p><p style="text-align:justify"><strong>Aseptic meningitis </strong></p><p style="text-align:justify">Aseptic meningitis was rapidly reversible on withdrawal of the drug, but recurred in a number of cases on re-exposure to either co-trimoxazole or to trimethoprim alone.</p><p style="text-align:justify"><strong>Pulmonary hypersensitivity reactions&nbsp; </strong></p><p style="text-align:justify">Cough, dyspnoea and lung infiltration may be early indicators of respiratory hypersensitivity which, while very rare, has been fatal.</p><p style="text-align:justify"><strong>Severe cutaneous adverse reactions (SCARs) </strong></p><p style="text-align:justify">Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported (see section 4.4).</p><p style="text-align:justify"><strong>Hepatobiliary disorders </strong></p><p style="text-align:justify">Jaundice cholestatic and hepatic necrosis may be fatal.</p><p style="text-align:justify"><strong>Effects associated with Pneumocystis jirovecii (P. carinii) Pneumonitis (PJP) management </strong></p><p style="text-align:justify">At the high dosages used for PJP management severe hypersensitivity reactions have been reported, necessitating cessation of therapy. Severe hypersensitivity reactions have been reported in PJP patients on re-exposure to trimethoprim-sulphamethoxazole, sometimes after a dosage interval of a few days. Rhabdomyolysis has been reported in HIV positive patients receiving co-trimoxazole for prophylaxis or treatment of PJP.</p><p style="text-align:justify"><strong><u>&nbsp;</u></strong></p><p><strong><u>To report any side effect(s):</u></strong></p><p style="margin-left:9.0pt; text-indent:-9.0pt">&middot; &nbsp;<strong>Saudi Arabia:</strong></p><p style="margin-left:9.0pt"><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p style="margin-left:9.0pt"><strong>Fax: </strong>+966-11-205-7662</p><p style="margin-left:9.0pt"><strong>Call NPC at </strong>+966-11-2038222, Exts: 2317-2356-2340</p><p style="margin-left:9.0pt"><strong>Reporting Hotline: </strong>19999</p><p style="margin-left:9.0pt"><strong>E-mail: </strong>npc.drug@sfda.gov.sa</p><p style="margin-left:9.0pt"><strong>Website: </strong>www.sfda.gov.sa/npc</p><p style="margin-left:9.0pt; text-align:justify; text-indent:-9.0pt">&middot; &nbsp;<strong>Other GCC States: </strong>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong><u>Symptoms </u></strong></p><p style="text-align:justify">Nausea, vomiting, dizziness and confusion are likely signs/symptoms of overdose. Bone marrow depression has been reported in acute trimethoprim overdose.</p><p style="text-align:justify"><strong><u>Management </u></strong></p><p style="text-align:justify">Dependent on the status of renal function administration of fluids is recommended if urine output is low.</p><p style="text-align:justify">Both trimethoprim and active sulphamethoxazole are moderately dialysable by haemodialysis. Peritoneal dialysis is not effective.</p><p style="text-align:justify">In cases of known, suspected or accidental overdose, stop therapy.</p><p style="text-align:justify">Acidification of the urine will increase the elimination of trimethoprim. Inducing diuresis plus alkalinisation of urine will enhance the elimination of sulphamethoxazole. Alkalinisation will reduce the rate of elimination of trimethoprim. Calcium folinate (5 to 10 mg/day) will reverse any folate deficiency effect of trimethoprim on the bone marrow should this occur. General supportive measures are recommended</p><p style="text-align:justify">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Pharmacotherapeutic group:&nbsp;</strong>antibacterials for systemic use &ndash; sulfonamides and trimethoprim&nbsp;Combinations of sulfonamides and trimethoprim, incl. derivatives;</p><p style="text-align:justify"><strong>ATC code: </strong>J01EE01</p><p style="text-align:justify"><strong><u>Mechanism of action</u></strong></p><p style="text-align:justify">Sulphamethoxazole competitively inhibits the utilisation of para-aminobenzoic acid in the synthesis of dihydrofolate by the bacterial cell resulting in bacteriostasis. Trimethoprim reversibly inhibits bacterial dihydrofolate reductase (DHFR), an enzyme active in the folate metabolic pathway converting dihydrofolate to tetrahydrofolate. Depending on the conditions the effect may be bactericidal. Thus trimethoprim and sulphamethoxazole block two consecutive steps in the biosynthesis of purines and therefore nucleic acids essential to many bacteria. This action produces marked potentiation of activity in vitro between the two agents.</p><p style="text-align:justify">Trimethoprim binds to plasmodial DHFR but less tightly than to the bacterial enzyme. The affinity of trimethoprim for mammalian DHFR is some 50,000 times less than for the corresponding bacterial enzyme.</p><p style="text-align:justify"><strong><u>Resistance</u></strong></p><p style="text-align:justify">In vitro studies have shown that bacterial resistance can develop more slowly with both sulphamethoxazole and trimethoprim in combination that with either sulphamethoxazole or trimethoprim alone.</p><p style="text-align:justify">Resistance to sulphamethoxazole may occur by different mechanisms. Bacterial mutations cause an increase the concentration of PABA and thereby out-compete with sulphamethoxazole resulting in a reduction of the inhibitory effect on dihydropteroate synthetase enzyme. Another resistance mechanism is plasmid-mediated and results from production of an altered dihydropteroate synthetase enzyme, with reduced affinity for sulphamethoxazole compared to the wild-type enzyme.</p><p style="text-align:justify">Resistance to trimethoprim occurs through a plasmid-mediated mutation which results in production of an altered dihydrofolate reductase enzyme having a reduced affinity for trimethoprim compared to the wild-type enzyme.</p><p style="text-align:justify"><strong><u>Susceptibility testing breakpoints</u></strong></p><p style="text-align:justify">Testing of trimethoprim sulphamethoxazole was performed using the common dilution series to assess the Minimum Inhibitory Concentration (MIC). The MIC breakpoints for resistance are those recommended by CLSI (Clinical and Laboratory Standards Institute &ndash; formerly the National Committee for Clinical Laboratory Standards (NCCLS) and EUCAST guidelines.</p><p style="text-align:justify"><strong><u>Pharmacodynamic effects</u></strong></p><p style="text-align:justify">The majority of common pathogenic bacteria are sensitive in vitro to trimethoprim and sulphamethoxazole at concentrations well below those reached in blood, tissue fluids and urine after the administration of recommended doses. In common with other antimicrobial agents in vitro activity does not necessarily imply that clinical efficacy had been demonstrated. These organisms include:</p><table cellspacing="0" cellpadding="0" border="1" style="width:98.1%"><tbody><tr><td style="vertical-align:top; width:100.0%"><p style="text-align:justify"><strong>Gram Negative</strong></p></td></tr><tr><td style="vertical-align:top; width:100.0%"><p style="text-align:justify"><em>Brucella spp.</em></p><p style="text-align:justify"><em>Citrobacter spp.</em></p><p style="text-align:justify"><em>Escherichia coli (including ampicillin-resistant strains)</em></p><p style="text-align:justify"><em>Haemophilus ducreyi</em></p><p style="text-align:justify"><em>Haemophilus influenzae (including ampicillin-resistant strains)</em></p><p style="text-align:justify"><em>Klebsiella/Enterobacter spp.</em></p><p style="text-align:justify"><em>Legionella pneumophila</em></p><p style="text-align:justify"><em>Morganella morganii (previously Proteus morganii)</em></p><p style="text-align:justify"><em>Neisseria spp.</em></p><p style="text-align:justify"><em>Proteus spp.</em></p><p style="text-align:justify"><em>Providencia spp. (including previously Proteus rettgeri)</em></p><p style="text-align:justify"><em>Certain Pseudomonas spp. except aeruginosa</em></p><p style="text-align:justify"><em>Salmonella spp. including&nbsp;</em>S.&nbsp;<em>typhi and paratyphi.</em></p><p style="text-align:justify"><em>Serratia marcescens.</em></p><p style="text-align:justify"><em>Shingella spp.</em></p><p style="text-align:justify"><em>Vibrio cholerae</em></p><p style="text-align:justify"><em>Yersinia spp.</em></p></td></tr><tr><td style="vertical-align:top; width:100.0%"><p style="text-align:justify"><strong>Gram positive</strong></p></td></tr><tr><td style="vertical-align:top; width:100.0%"><p style="text-align:justify"><em>Listeria monocytogenes.</em></p><p style="text-align:justify"><em>Nocardia spp.</em></p><p style="text-align:justify"><em>Staohylococcus aureus.</em></p><p style="text-align:justify"><em>Staphylococcus epidermidis and saprophyticus</em></p><p style="text-align:justify"><em>Enterococcus faecalis.</em></p><p style="text-align:justify"><em>Streptococcus pneumoni ae.</em></p><p style="text-align:justify"><em>Streptococcus viridans.</em></p></td></tr></tbody></table><p style="text-align:justify">Many strains of Bacteroides fragilis are sensitive. Some strains of&nbsp;<em>Campylobacter fetus subsp. Jejuni</em>&nbsp;and chlamydia are sensitive without evidence of synergy. Some varieties of non-tuberculous mycobacteria are sensitive to sulphamethoxazole but not trimethoprim. Mycoplasmas, Ureaplasma urealyticum, Mycobacterium tuberculosis and Treponema pallidum are insensitive.</p><p style="text-align:justify">Satisfactory sensitivity testing is achieved only with recommended media free from inhibitory substances especially thymidine and thymine.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">5.2 Pharmacokinetic properties</p><p style="text-align:justify"><strong><u>Absorption:</u></strong></p><p style="text-align:justify">After oral administration trimethoprim and sulphamethoxazole are rapidly and nearly completely absorbed. The presence of food does not appear to delay absorption. Peak levels in the blood occur between one and four hours after ingestion and the level attained is dose related. Effective levels persist in the blood for up to 24 hours after a therapeutic dose. Steady state levels in adults are reached after dosing for 2-3 days. Neither component has an appreciable effect on the concentrations achieved in the blood by the other.</p><p style="text-align:justify"><strong><u>Distribution:</u></strong></p><p style="text-align:justify">Approximately 50% of trimethoprim in the plasma is protein bound</p><p style="text-align:justify">Tissue levels of trimethoprim are generally higher than corresponding plasma levels, the lungs and kidneys showing especially high concentrations. Trimethoprim concentrations exceed those in plasma in the case of bile, prostatic fluid and tissue, saliva, sputum and vaginal secretions. Levels in the aqueous humor, breast milk, cerebrospinal fluid, middle ear fluid, synovial fluid and tissue (intestinal) fluid are adequate for antibacterial activity. Trimethoprim passes into amniotic fluid and foetal tissues reaching concentrations approximating those of maternal serum.</p><p style="text-align:justify">Approximately 66% of sulphamethoxazole in the plasma is protein bound.</p><p style="text-align:justify">The concentration of active sulphamethoxazole in amniotic fluid, aqueous humour, bile, cerebrospinal fluid, middle ear fluid, sputum, synovial fluid and tissue (interstitial) fluid is of the order of 20-50% of the plasma concentration.</p><p style="text-align:justify"><strong><u>Biotransformation</u></strong></p><p style="text-align:justify">Renal excretion of intact sulphamethoxazole accounts for 15-30% of the dose. This drug is more extensively metabolised than trimethoprim, via acetylation, oxidation or glucuronidation. Over a 72 hour period, approximately 85% of the dose can be accounted for in the urine as unchanged drug plus the major (N4-acetylated) metabolite.</p><p style="text-align:justify"><strong><u>Elimination</u></strong></p><p style="text-align:justify">The half-life of trimethoprim in man is in the range 8.6 to 17 hours in the presence of normal renal function. There appears to be no significant difference in the elderly compared with young patients.</p><p style="text-align:justify">The principle route of excretion of trimethoprim is renal and approximately 50% of the dose is excreted in the urine within 24 hours as unchanged drug. Several metabolites have been identified in the urine. Urinary concentration of trimethoprim varies widely.</p><p style="text-align:justify">The half-life of sulphamethoxazole in man is approximately 9-11 hours in the presence of normal renal function. There is no change in the half-life of active sulphamethoxazole with a reduction in renal function but there is prolongation of the half-life of the major, acetylated metabolite when the creatinine clearance is below 25 ml/minute.</p><p style="text-align:justify">The principle route of excretion of sulphamethoxazole is renal; between 15% and 30% of the dose recovered in the urine is in the active form.</p><p style="text-align:justify"><strong><u>Special patient populations</u></strong></p><p style="text-align:justify"><strong>Renal impairment</strong></p><p style="text-align:justify">The elimination half-life of trimethoprim is increased by a factor of 1.5-3.0 when the creatinine clearance is less than 10 mL/minute. When the creatinine clearance falls below 30 mL/min the dosage of co-trimoxazole should be reduced (see section 4.2).</p><p style="text-align:justify"><strong>Hepatic impairment</strong></p><p style="text-align:justify">Caution should be exercised when treating patients with severe hepatic impairment as there may be changes in the absorption and biotransformation of trimethoprim and sulphamethoxazole</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Older patients</strong></p><p style="text-align:justify">In older patients, a slight reduction in renal clearance of sulphamethoxazole but not trimethoprim has been observed.</p><p style="text-align:justify"><strong>Paediatric population</strong></p><p style="text-align:justify">The pharmacokinetics in the paediatric population with normal renal function of both components of suspension, trimethoprim and sulphamethoxazole are age dependent. Elimination of trimethoprim - sulphamethoxazole is reduced in neonates, during the first two months of life, thereafter both trimethoprim and sulphamethoxazole show a higher elimination with a higher body clearance and a shorter elimination half-life. The differences are most prominent in young infants (&gt; 1.7 months up to 24 months) and decrease with increasing age, as compared to young children (1 year up to 3.6 years), children (7.5 years and &lt; 10 years) and adults (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After oral administration trimethoprim and sulphamethoxazole &nbsp;are rapidly and nearly completely absorbed. The presence of food does not appear to delay absorption. Peak levels in the blood occur between one and four hours after ingestion and the level attained is dose related. Effective levels persist in the blood for up to 24 hours after a therapeutic dose. Steady state levels in adults are reached after dosing for 2-3 days. Neither component has an appreciable effect on the concentrations achieved in the blood by the other.</p><p>Trimethoprim is a weak base with a pKa of 7.4. It is lipophilic. Tissue levels of trimethoprim are generally higher than corresponding plasma levels, the lungs and kidneys showing especially high concentrations. Trimethoprim concentrations exceed those in plasma in the case of bile, prostatic fluid and tissue, saliva, sputum and vaginal secretions. Levels in the aqueous humor, breast milk, cerebrospinal fluid, middle ear fluid, synovial fluid and tissue (intestinal) fluid are adequate for antibacterial activity. Trimethoprim passes into amniotic fluid and foetal tissues reaching concentrations approximating those of maternal serum.</p><p>Approximately 50% of trimethoprim in the plasma is protein bound. The half-life in man is in the range 8.6 to 17 hours in the presence of normal renal function. It is increased by a factor of 1.5 to 3.0 when the creatinine clearance is less than 10 ml/minute. There appears to be no significant difference in the elderly compared with young patients.</p><p>The principal route of excretion of trimethoprim is renal and approximately 50% of the dose is excreted in the urine within 24 hours as unchanged drug. Several metabolites have been identified in the urine. Urinary concentrations of trimethoprim vary widely.</p><p>Sulphamethoxazole &nbsp;is a weak acid with a pKa of 6.0. The concentration of active sulphamethoxazole &nbsp;in a variety of body fluids is of the order of 20 to 50% of the plasma concentration.</p><p>Approximately 66% of sulphamethoxazole &nbsp;in the plasma is protein bound and the principal route of excretion of sulphamethoxazole &nbsp;is renal. The half-life in man is approximately 9 to 11 hours in the presence of normal renal function. There is no change in the half-life of active sulphamethoxazole &nbsp;with a reduction in renal function but there is prolongation of the half-life of the major, acetylated metabolite when the creatinine clearance is below 25 ml/minute.</p><p>The principle route of excretion of sulphamethoxazole is renal; between 15% and 30% of the dose recovered in the urine is in the active form. In elderly patients there is a reduced renal clearance of sulphamethoxazole .</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:0cm; text-align:justify">At doses generally in excess of recommended human therapeutic dose, trimethoprim and sulphamethoxazole have been reported to cause cleft palate and other foetal abnormalities in rats, findings typical of a folate antagonist. Effects with trimethoprim were preventable by co-administration of dietary folate. In rabbits, foetal loss was seen at doses of trimethoprim in excess of human therapeutic doses.</p><p style="margin-left:0cm; margin-right:0cm; text-align:justify">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" border="0" style="width:645px"><tbody><tr><td style="vertical-align:top"><table cellspacing="0" cellpadding="0" border="0" style="width:387.0pt"><tbody><tr><td style="vertical-align:top; width:387.0pt"><p style="text-align:justify"><strong><u>Inactive Ingredients:</u></strong></p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Glycerol</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Saccharin sodium</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Citric acid monohydrate</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Sucrose</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Tween 80</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Apricot flavour</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Banana flavour</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Raspberry red colour</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->FD&amp;C red 40</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->CMC sodium</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Aluminium magnesium silicate (veegum HV)</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Methyl paraben</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Propyl paraben</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Propylene glycol</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Sorbitol 70%</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Polyvinyl pyrrolidone (PVP-K-30)</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Colloidal silicon dioxide (Aerosil 200)</p></td></tr><tr><td style="vertical-align:top; width:387.0pt"><p style="margin-left:36.0pt; text-align:justify; text-indent:-23.4pt"><!--[if !supportLists]-->18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Purified water.</p></td></tr></tbody></table></td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Trimol 50mL Suspension: 24 months from the date of manufacturing
	Trimol 100mL Suspension: 48 months from the date of manufacturing

After opening: one month

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C. After opening, use within one month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:7.65pt; margin-right:0cm; text-align:justify; text-indent:-7.05pt"><!--[if !supportLists]-->&sect; <!--[endif]--><strong>Pack of 50mL:</strong> Suspension packed in an Amber coloured glass bottle provided with CRC cap, packed in a printed carton along with a leaflet.</p><p style="margin-left:7.65pt; margin-right:0cm; text-align:justify; text-indent:-7.05pt"><!--[if !supportLists]-->&sect; <!--[endif]--><strong>Pack of 100mL:</strong> Suspension packed in an Amber coloured glass bottle provided with CRC cap, packed in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates
P.O. Box 997
Tel. No.:   (9717) 2 461 461
Fax No.:   (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08. December. 2019

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>